Jennifer Gunter
Obstetrician-gynecologist and author of The Vagina Bible and The Menopause Manifesto. Writes The Vajenda newsletter on women's health, menopause, hormone therapy and health misinformation.
Jennifer Gunter did not write this page. ppll compiled it from their own words, each linked to the source. Is this you? · Report a mistake
What they believe
-
Studies using the TriNetX database are not reliable enough to determine causal effects of testosterone.
Studies using the TriNexT database have too many issues to be highly reliable regarding causal effects of testosterone.
vajenda.substack.comSaid 21 Oct 2026This on korrents
-
Clinical guidelines can influence insurance coverage and drug pricing.
While guidelines don't compel anyone, they can influence insurers, pharmacy benefit managers, or governments to cover therapies and may also affect the price.
vajenda.substack.comSaid 16 Oct 2026This on korrents
The bold line is korrents’ wording; the quote is theirs. These 2: what they wrote before what they said aloud, one per source, newest first.
Beliefs
Korrents What they believe 16 beliefs — each backed by an exact quote.
Each is a — compiled by korrents.com, not by them: the one-line wordings are korrents', the quotes are theirs.
Recent
Studies using the TriNetX database are not reliable enough to determine causal effects of testosterone.
Studies using the TriNexT database have too many issues to be highly reliable regarding causal effects of testosterone.
Testosterone and Heart Disease Said 21 Oct 2026
The latest testosterone abstract does not prove that testosterone causes heart disease in postmenopausal women.
This latest testosterone abstract does not prove that testosterone causes heart disease in postmenopausal women, just as last year's estrogen abstract did not prove that hormone therapy prevents disease in perimenopause.
Testosterone and Heart Disease Said 21 Oct 2026
Clinical guidelines can influence insurance coverage and drug pricing.
While guidelines don't compel anyone, they can influence insurers, pharmacy benefit managers, or governments to cover therapies and may also affect the price.
The Price of a Hot Flash Said 16 Oct 2026
Show 13 more
The ACP guideline's exclusion of tibolone lacks sufficient evidence to justify safety concerns.
The guideline excluded tibolone for what the authors write are "safety reasons," but they provide no analysis showing why its safety profile would preclude its use for hot flashes and night sweats.
The Price of a Hot Flash Said 16 Oct 2026
Demoting drugs to a lower tier based on cost can create a self-fulfilling prophecy regarding their clinical use.
Demoting a drug to a third tier based on cost becomes a self-fulfilling prophecy, as many insurers and pharmacy benefit managers look at these tiers to design coverage or as excuses to exclude the more expensive drugs.
The Price of a Hot Flash Said 16 Oct 2026
Bone loss during perimenopause is likely caused by multiple hormones.
Bone loss during perimenopause is likely a multi-hormone event.
Bone Health Without the Hype Said 13 Sept 2026
Denosumab requires continuous use because stopping it can lead to rapid bone loss.
Denosumab is a fantastic antiresorptive medication, but people need to be on it continuously and cannot just stop it as rapid loss of bone in the 12 months after stopping can occur.
Bone Health Without the Hype Said 13 Sept 2026
Compounded testosterone products for women may not be formulated consistently or match their labeling.
Women who are using compounded testosterone have every reason to worry that their products may not be formulated consistently or match the labeling.
The Problem with Compounded Testosterone Said 4 Sept 2026
There are no regulations in the United States and Canada requiring compounders to prove their products contain what they claim or that they work.
In the United States and Canada, there are no regulations requiring compounders to prove that what they make contains what it claims or that it actually works.
The Problem with Compounded Testosterone Said 4 Sept 2026
The amount of testosterone in compounded gels and creams can vary substantially from the prescribed concentration.
The one study we have showed that the amount of testosterone in compounded gels and creams can vary substantially from the prescribed concentration, which is not unexpected.
The Problem with Compounded Testosterone Said 4 Sept 2026
The results of the Squires et al. study suggest that MHT is not broadly neuroprotective.
The results are precisely the pattern that argues AGAINST broad use of MHT to prevent dementia. The women who benefited the most had shorter reproductive years or surgical menopause, which, if the results of the study are true (and we can't know if they are as it is observational...and we will get into all the issues with the UK Biobank and MHT studies shortly), they support the conclusion that MHT is NOT broadly neuroprotective.
Before You Share That New "HRT Prevents Dementia" Study, Read the Fine Print Said 28 Aug 2026
Observational studies of MHT can be biased by the healthy-user effect.
One big reason is that healthier, wealthier women tend to use MHT, which creates a meaningful difference between MHT users and non-users, so we must be careful when attributing any benefit to MHT rather than to the healthy-user effect.
Before You Share That New "HRT Prevents Dementia" Study, Read the Fine Print Said 28 Aug 2026
The UK Biobank is not a representative sample of the general U.K. population.
People in the UK Biobank are overall healthier than the general U.K. population, so it is not a representative sample of people on or off MHT.
Before You Share That New "HRT Prevents Dementia" Study, Read the Fine Print Said 28 Aug 2026
There is no established clinical syndrome or testosterone level that defines testosterone deficiency for women.
The Endocrine Society (2014) and the Global Consensus Statement on Testosterone (2019) both concluded there is no established clinical syndrome or testosterone level that defines testosterone deficiency for women.
MIDI and the Making of Female Testosterone Deficiency Said 30 Jul 2026
Testosterone levels do not reliably distinguish women with symptoms from those without.
Testosterone levels do not reliably distinguish women with symptoms from those without.
MIDI and the Making of Female Testosterone Deficiency Said 30 Jul 2026
Studies have not demonstrated a meaningful benefit of using testosterone therapy outside of sexual desire disorders.
Outside of sexual desire disorders, studies have not demonstrated a meaningful benefit of using testosterone therapy.
MIDI and the Making of Female Testosterone Deficiency Said 30 Jul 2026
What is a korrent?
A korrent is a belief a person has stated in their own words: one sentence stating the claim, backed by a quote and a source, kept at korrents.com.
Under a name here, the quoted block is what they actually said. The korrent beneath it is the claim those words support, in korrents' wording — tap it to see the record, its source, and who else holds it.
Nobody here wrote their own korrents. They are compiled from public statements, and a person can change their mind, which is recorded too.
Where they publish
Newsletter The Vajenda Several posts a week on menopause, hormones, new studies and wellness claims
Link verified 24 Oct 2026.
x.com @DrJenGunter Posts on women's health and misinformation
Link verified 24 Oct 2026.
About the English under a post
Some people here publish in a language other than English. Where they do, this site shows a machine translation beneath the post, in this typeface — the site's own, not theirs.
The post itself is never changed, moved or hidden: what is set in the serif above is exactly what the person published, and it is what to quote them on. A translation can be wrong in ways that matter, especially about tone.
Only the post's own words are translated. A quoted post, a linked article and a belief on korrents.com are left in their original language.